| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.0000258972.10109.FF |
| P698 | PubMed publication ID | 17272745 |
| P50 | author | Luis M Blanco-Colio | Q55542660 |
| Alberto Ortiz | Q56855135 | ||
| Olivier Meilhac | Q57244186 | ||
| Jose L Martín-Ventura | Q62131494 | ||
| Jesus Egido | Q120487826 | ||
| P2093 | author name string | Jean-Baptiste Michel | |
| Begoña Muñóz-García | |||
| Jose A Páramo | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| atherosclerosis | Q12252367 | ||
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 916-922 | |
| P577 | publication date | 2007-02-01 | |
| P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
| P1476 | title | Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis | |
| P478 | volume | 27 |
| Q33931813 | A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. |
| Q37042084 | Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients |
| Q50690444 | Advanced glycation end products attenuate the function of tumor necrosis factor-like weak inducer of apoptosis to regulate the inflammatory response. |
| Q34460820 | Antibody phage display assisted identification of junction plakoglobin as a potential biomarker for atherosclerosis |
| Q37500635 | Biomarkers in cardiovascular medicine |
| Q41648597 | Characterization of Lamprey BAFF-like Gene: Evolutionary Implications |
| Q51246335 | Clinical significance of serum interleukin-8 and soluble tumor necrosis factor-like weak inducer of apoptosis levels in patients with diabetic nephropathy. |
| Q33944773 | Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation |
| Q48421210 | Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure |
| Q35958888 | Evaluation of serum sTWEAK and sCD163 levels in patients with acute and chronic coronary artery disease |
| Q42492245 | Expression of TWEAK in normal human skin, dermatitis and epidermal neoplasms: association with proliferation and differentiation of keratinocytes. |
| Q37724036 | Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice |
| Q35866999 | HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels |
| Q28071723 | Immunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndrome |
| Q34450860 | Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells |
| Q26851535 | Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus |
| Q35689476 | N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease |
| Q27000373 | Novel biomarkers of abdominal aortic aneurysm disease: identifying gaps and dispelling misperceptions |
| Q28088373 | Novel methodologies for biomarker discovery in atherosclerosis |
| Q90472914 | Periodontitis and vascular inflammatory biomarkers: an experimental in vivo study in rats |
| Q36015686 | Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease |
| Q33321675 | Proteomic analysis in cardiovascular diseases. |
| Q37738351 | Proteomic and metabolomic profiles in atherothrombotic vascular disease |
| Q51615648 | Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential. |
| Q33335986 | Proteomics in atherosclerosis. |
| Q36787244 | Proteomics in atherothrombosis: a future perspective |
| Q38780174 | Proteomics in cardiovascular disease: recent progress and clinical implication and implementation. |
| Q38106664 | Proteomics of plaques and novel sources of potential biomarkers for atherosclerosis |
| Q38034137 | Recent advances in proteomic technologies applied to cardiovascular disease. |
| Q50456399 | Reduced circulating levels of TWEAK are associated with gestational diabetes mellitus. |
| Q37681640 | Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk |
| Q31152445 | Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection |
| Q34399571 | Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. |
| Q33825980 | Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study |
| Q36686970 | Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD. |
| Q34751855 | Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes |
| Q34815993 | Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. |
| Q43801106 | Soluble TWEAK levels are independently associated with coronary artery disease severity in patients with stage 2-3 kidney disease. |
| Q38614592 | Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection. |
| Q37415728 | Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease |
| Q46354917 | Soluble TWEAK plasma levels increase after renal transplantation and associate with the improvement of endothelial function |
| Q83822346 | Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension |
| Q56529470 | Soluble Tumor Necrosis Factor Like Weak Inducer of Apoptosis and Vitamin D in Hemodialysis Patients: Relation to Carotid Intima-Media Thickness |
| Q40640099 | TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFκB. |
| Q27318227 | TWEAK promotes peritoneal inflammation |
| Q34764239 | TWEAK-independent Fn14 self-association and NF-κB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain |
| Q37494039 | TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases. |
| Q64962070 | TWEAK/Fn14 mediates atrial-derived HL-1 myocytes hypertrophy via JAK2/STAT3 signalling pathway. |
| Q38177788 | TWEAK: A New Player in Obesity and Diabetes. |
| Q94418605 | The Evaluation of Serum Tumor Necrosis Factor-Like Weak Inducer of Apoptosis, Interleukin-6, Fetuin-A, Homeostatic Model Assessment-Insulin Resistance, and Insulin Levels in Rheumatoid Arthritis Patients in Clinical Remission |
| Q45953803 | The relationships between serum sTWEAK, FGF-23 levels, and carotid atherosclerosis in renal transplant patients. |
| Q38638020 | The role of tumor necrosis factor-like weak inducer of apoptosis in atherosclerosis via its two different receptors |
| Q38552059 | Transition from identity to bioactivity-guided proteomics for biomarker discovery with focus on the PF2D platform. |
| Q35026182 | Tumor necrosis factor-like weak inducer of apoptosis or Fn14 deficiency reduce elastase perfusion-induced aortic abdominal aneurysm in mice. |
| Q37871569 | Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK. |
| Q37610301 | Vascular proteomics, a translational approach: from traditional to novel proteomic techniques. |
Search more.